1 Efficacy and safety of R-GEMOX in relapsed or refractory diffuse large B-cell lymphoma: A single-center experience in Vietnam / Dinh Thi Hai Duyen, Tran Thi Huyen, Nguyen Thi Mai Lan // .- 2025 .- Tập 190 - 5E16 .- P. 12-19 .- 610

Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL), yet a substantial proportion of patients experience relapse or refractory disease following initial therapy. Among various salvage regimens, R-GEMOX - comprising rituximab, gemcitabine, and oxaliplatin - has shown promising efficacy and a tolerable safety profile. This retrospective cohort study aimed to evaluate the treatment outcomes and adverse events associated with R-GEMOX in patients with relapsed or refractory CD20-positive DLBCL treated at Hanoi Oncology Hospital. A total of 39 patients who received at least four cycles of R-GEMOX between January 2018 and May 2024 were included. Treatment response was assessed using the Lugano 2014 criteria, and toxicities were graded per CTCAE v4.0.